Josan, Kiranbir
Neilan, Tomas G. http://orcid.org/0000-0003-4356-8176
Article History
First Online: 21 December 2022
Competing interests
: T.G.N. has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CRO Oncology, Genentech, H3 Biomedicine, Roche and Sanofi, and has received grant funding from AstraZeneca and Bristol Myers Squibb for work related to the cardiovascular complications of immune checkpoint inhibitors. K.J. declares no competing interests.